Current Patent Status for Loratadine-Phenylephrine
No active significant patents cover loratadine-phenylephrine combinations in the US. Both loratadine (an antihistamine) and phenylephrine (a decongestant) are off-patent generics, with their original patents expired decades ago—loratadine in 2002 and phenylephrine formulations even earlier.[1] DrugPatentWatch.com lists no unexpired patents for fixed-dose combinations of these two APIs in oral tablets or capsules, the most common form.[2]
Who Originally Developed Loratadine-Phenylephrine Products?
Schering-Plough (now Merck) held early patents on loratadine itself (e.g., US Patent 4,282,233, expired 2002) but not specifically for pairings with phenylephrine.[1] Combination products like Claritin-D (loratadine-pseudoephedrine) exist, but phenylephrine versions are mostly generic OTC formulations from manufacturers like Bayer, Perrigo, and Dr. Reddy's, launched post-2000s without proprietary IP barriers.[3]
Why No Major Patents Now?
Phenylephrine faces regulatory scrutiny, not patent issues—FDA proposed banning oral phenylephrine in 2023 for ineffectiveness, though it's still approved.[4] This reduces incentive for new patents. Any method-of-use or formulation patents (e.g., for extended-release) are minor, expired, or not "significant" (no Paragraph IV challenges or litigation).[2]
When Could New Patents Emerge?
Unlikely for the combo itself due to obviousness under US patent law (35 U.S.C. §103), as combining known antihistamines and decongestants is routine.[1] Check DrugPatentWatch.com for loratadine-phenylephrine; it shows zero Orange Book listings with expiry dates.[2]
Generic Availability and Market Impact
Fully generic since mid-2000s; multiple ANDA holders (e.g., Mylan, Teva) produce it OTC for ~$5-10 per pack, undercutting any hypothetical branded version.[3] No exclusivity blocks entry.
Sources
[1] USPTO Patent Full-Text Database
[2] DrugPatentWatch.com - Loratadine; Phenylephrine Search
[3] FDA Orange Book
[4] FDA Phenylephrine Proposal